Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Christgen M, Gluz O, Harbeck N, Kates RE, Raap M, Christgen H, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Krabisch P, Just M, Augustin D, Graeser M, Baehner F, Wuerstlein R, Nitz U, Kreipe H; West German Study Group PlanB Investigators. Christgen M, et al. Among authors: malter w. Cancer. 2020 Nov 15;126(22):4847-4858. doi: 10.1002/cncr.33104. Epub 2020 Aug 11. Cancer. 2020. PMID: 32780421 Free article.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N. Nitz U, et al. Among authors: malter w. Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29. Breast Cancer Res Treat. 2017. PMID: 28664507 Free PMC article.
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
Wunderle M, Pretscher J, Brucker SY, Volz B, Hartmann A, Fiessler C, Hein A, Häberle L, Jud SM, Lux MP, Janni W, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kümmel S, Martin B, Thomssen C, Graf H, Wolf C, Bayer CM, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb TF, Nabieva N, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Wallwiener D, Rack B, Fehm T, Rody A, Maass N, Beckmann MW, Fasching PA, Rauh C. Wunderle M, et al. Among authors: malter w. Breast Cancer Res Treat. 2019 Apr;174(2):453-461. doi: 10.1007/s10549-018-05115-6. Epub 2019 Jan 2. Breast Cancer Res Treat. 2019. PMID: 30603996 Clinical Trial.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N. Nitz U, et al. Among authors: malter w. Breast Cancer Res Treat. 2019 May;175(1):265-266. doi: 10.1007/s10549-018-05105-8. Breast Cancer Res Treat. 2019. PMID: 30632020 Free PMC article.
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kuemmel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates RE, Kreipe HH, Harbeck N; West German Study Group PlanB Investigators. Nitz U, et al. Among authors: malter w. J Clin Oncol. 2019 Apr 1;37(10):799-808. doi: 10.1200/JCO.18.00028. Epub 2019 Feb 20. J Clin Oncol. 2019. PMID: 30785826 Clinical Trial.
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Nabieva N, Häberle L, Brucker SY, Janni W, Volz B, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kuemmel S, Martin B, Thomssen C, Graf H, Wolf C, Lux MP, Bayer CM, Rauh C, Hack CC, Almstedt K, Gass P, Heindl F, Brodkorb T, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Rack B, Beckmann MW, Fehm T, Rody A, Maass N, Hein A, Fasching PA. Nabieva N, et al. Among authors: malter w. Int J Cancer. 2019 Oct 15;145(8):2114-2121. doi: 10.1002/ijc.32294. Epub 2019 Apr 2. Int J Cancer. 2019. PMID: 30901076 Clinical Trial.
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Hack CC, Häberle L, Brucker SY, Janni W, Volz B, Loehberg CR, Hartkopf AD, Walter CB, Baake G, Fridman A, Malter W, Wuerstlein R, Harbeck N, Hoffmann O, Kuemmel S, Martin B, Thomssen C, Graf H, Wolf C, Lux MP, Bayer CM, Rauh C, Almstedt K, Gass P, Heindl F, Brodkorb T, Willer L, Lindner C, Kolberg HC, Krabisch P, Weigel M, Steinfeld-Birg D, Kohls A, Brucker C, Schulz V, Fischer G, Pelzer V, Rack B, Beckmann MW, Fehm T, Rody A, Maass N, Hein A, Fasching PA, Nabieva N. Hack CC, et al. Among authors: malter w. Breast. 2020 Apr;50:11-18. doi: 10.1016/j.breast.2019.12.017. Epub 2020 Jan 8. Breast. 2020. PMID: 31958661 Free PMC article. Clinical Trial.
70 results